Generic placeholder image

Mini-Reviews in Medicinal Chemistry


ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Angiogenesis as a therapeutic target in breast cancer

Author(s): Angelos K. Koutras, Ioannis Starakis, Dionysia Lymperatou and Haralabos P. Kalofonos

Volume 12, Issue 12, 2012

Page: [1230 - 1238] Pages: 9

DOI: 10.2174/138955712802761988

Price: $65


Current evidence indicates that angiogenesis plays an important role in the pathogenesis of several malignancies, including breast cancer. Bevacizumab is a monoclonal antibody that targets the vascular endothelial growth factor (VEGF). Recent clinical data have demonstrated that the addition of bevacizumab to first-line chemotherapy improves the progression-free survival of patients with advanced breast cancer. This review presents an update on the role of bevacizumab, as well as other anti-angiogenic agents in the management of patients with breast carcinoma.

Keywords: Angiogenesis, bevacizumab, breast cancer, treatment.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy